	US 11,684,600 B2
	Composition of active agents to positively affect a robust mammalian endocannabinoid system tone to better address age related discomfort
Robert Rager, Silver Spring, MD (US)
Assigned to COMPACT DISC INCORPORATED, Silver Spring, MD (US)
Filed by Compact Disc Incorporated, Silver Spring, MD (US)
Filed on Mar. 4, 2021, as Appl. No. 17/191,996.
Claims priority of provisional application 63/100,221, filed on Mar. 4, 2020.
Prior Publication US 2021/0275485 A1, Sep. 9, 2021
Int. Cl. A61K 31/202 (2006.01); A61K 31/165 (2006.01); A61K 31/015 (2006.01); A61K 31/353 (2006.01); A61K 31/12 (2006.01); A61K 9/00 (2006.01); A61K 9/16 (2006.01)

CPC A61K 31/202 (2013.01) [A61K 9/0014 (2013.01); A61K 9/0053 (2013.01); A61K 9/16 (2013.01); A61K 31/015 (2013.01); A61K 31/12 (2013.01); A61K 31/165 (2013.01); A61K 31/353 (2013.01)]

18 Claims

1. A method of treating inflammatory and neuropathic pain in a mammal comprising:

administering to a mammal in need thereof a synergistic pharmaceutical daily dosage form comprising: between about 1 and about 2% by weight of palmitoylethanolamide (PEA) in an ultramicronized form, between about 10 and about 30% by weight of beta-caryophyllene (BCP) and between about 10 and about 30% by weight of docosahexaenoic acid (DHA) in liquid form;

wherein a daily dose of the palmitoylethanolamide (PEA) does not exceed about 1200 mg/day, a daily dose of the beta-caryophyllene (BCP) does not exceed about 0.1 mL/kg per kg body weight of the mammal, and a daily dose of the docosahexaenoic acid (DHA) does not exceed about 10 mg/kg per kg body weight of the mammal.